To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
KKR-backed Biosynth Carbosynth acquires vivitide
Biosynth Carbosynth, which is backed by KKR, has acquired vivitide, a provider of custom peptides and antibodies for the life sciences and biotech industry.
